CD34+ stem cell augmentation of allogeneic, elutriated marrow grafts improves engraftment but cyclosporine A is still required to reduce GVHD and morbidity

Transplant Proc. 1997 Feb-Mar;29(1-2):728-32. doi: 10.1016/s0041-1345(96)00442-3.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antigens, CD
  • Antigens, CD34*
  • Bone Marrow Cells
  • Bone Marrow Transplantation / immunology*
  • Cell Separation
  • Colony-Forming Units Assay
  • Cyclosporine / therapeutic use*
  • Graft vs Host Disease / epidemiology
  • Graft vs Host Disease / prevention & control*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Leukemia / therapy
  • Lymphoma / therapy
  • Middle Aged
  • Morbidity
  • Myelodysplastic Syndromes / therapy
  • Patient Selection
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Transplantation, Homologous

Substances

  • Antigens, CD
  • Antigens, CD34
  • Immunosuppressive Agents
  • Cyclosporine